Clinicians typically start patients at the middle ODT dose (5 mg) when switching from low-dose injectables (0.25 to 0.5 mg weekly) and titrate based on response
PubMed Central, doi:10.1097/MD.0000000000013337
Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis
we don't know if there are downsides to artificially promoting it No regulatory approval it remains a research compound This doesn't mean Dihexa is dangerous it means it requires more caution and conservative dosing than better-studied peptides
Individual factors including concentration used, baseline skin condition, age, lifestyle, and complementary skincare significantly affect benefit retention creating substantial variation in personal outcomes requiring experimentation for determining optimal individual approach
To date, studies have reported minimal adverse effects at typical research-level dosages
